Literature DB >> 16968692

Atypical haemolytic uraemic syndrome.

David Kavanagh1, Timothy H J Goodship, Anna Richards.   

Abstract

The haemolytic uraemic syndrome (HUS) is characterized by the triad of thrombocytopenia, microangiopathic haemolytic anaemia and acute renal failure. HUS may be classified as either diarrhoeal-associated or non-diarrhoeal/atypical (aHUS). aHUS has recently been shown to be a disease of complement dysregulation, with 50% of cases involving the complement regulatory genes, factor H (CFH), membrane cofactor protein (MCP; CD46), and factor I (IF). However, incomplete penetrance of mutations in each of these genes is reported. This suggests that a precipitating event or trigger is required to unmask the complement regulatory deficiency. The reported precipitating events predominantly cause endothelial injury. Discovery of these mutations has revealed important genotype-phenotype correlations. MCP-HUS has a better prognosis and a better outcome after transplantation than either CFH-HUS or IF-HUS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16968692     DOI: 10.1093/bmb/ldl004

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  46 in total

Review 1.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

2.  Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis.

Authors:  Paula Bertram; Antonina M Akk; Hui-fang Zhou; Lynne M Mitchell; Christine T N Pham; Dennis E Hourcade
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-02

Review 3.  Thrombotic microangiopathy with targeted cancer agents.

Authors:  John A Blake-Haskins; Robert J Lechleider; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

Review 4.  Review: Complement and its regulatory proteins in kidney diseases.

Authors:  Allison M Lesher; Wen-Chao Song
Journal:  Nephrology (Carlton)       Date:  2010-10       Impact factor: 2.506

5.  Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient.

Authors:  Micah R Chan; Christie P Thomas; Jose R Torrealba; Arjang Djamali; Luis A Fernandez; Carla J Nishimura; Richard J H Smith; Millie D Samaniego
Journal:  Am J Kidney Dis       Date:  2008-09-21       Impact factor: 8.860

6.  Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids.

Authors:  Peter X Shaw; Li Zhang; Ming Zhang; Hongjun Du; Ling Zhao; Clara Lee; Seanna Grob; Siok Lam Lim; Guy Hughes; Janet Lee; Matthew Bedell; Mark H Nelson; Fang Lu; Martin Krupa; Jing Luo; Hong Ouyang; Zhidan Tu; Zhiguang Su; Jin Zhu; Xinran Wei; Zishan Feng; Yaou Duan; Zhenglin Yang; Henry Ferreyra; Dirk-Uwe Bartsch; Igor Kozak; Liangfang Zhang; Feng Lin; Hui Sun; Hong Feng; Kang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-08       Impact factor: 11.205

7.  Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein.

Authors:  Dennis E Hourcade; Lynne M Mitchell
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

Review 8.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

Review 9.  Genetics and complement in atypical HUS.

Authors:  David Kavanagh; Tim Goodship
Journal:  Pediatr Nephrol       Date:  2010-06-06       Impact factor: 3.714

10.  Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project.

Authors:  Ozge Ceyhan-Birsoy; Jaclyn B Murry; Kalotina Machini; Matthew S Lebo; Timothy W Yu; Shawn Fayer; Casie A Genetti; Talia S Schwartz; Pankaj B Agrawal; Richard B Parad; Ingrid A Holm; Amy L McGuire; Robert C Green; Heidi L Rehm; Alan H Beggs
Journal:  Am J Hum Genet       Date:  2019-01-03       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.